HighTide Therapeutics (HKSE:02511) Debt-to-Equity : 0.04 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Debt-to-Equity?

HighTide Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$5.39 Mil. HighTide Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$19.49 Mil. HighTide Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$590.66 Mil. HighTide Therapeutics's debt to equity for the quarter that ended in Jun. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for HighTide Therapeutics's Debt-to-Equity or its related term are showing as below:

HKSE:02511' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: -0.01 Max: 0.04
Current: 0.04

During the past 3 years, the highest Debt-to-Equity Ratio of HighTide Therapeutics was 0.04. The lowest was -0.03. And the median was -0.01.

HKSE:02511's Debt-to-Equity is ranked better than
74.98% of 1011 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:02511: 0.04

HighTide Therapeutics Debt-to-Equity Historical Data

The historical data trend for HighTide Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Debt-to-Equity Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-0.03

-0.02

0.02

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial			N/A	-0.02	-0.01	0.02	0.04

Competitive Comparison of HighTide Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, HighTide Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Debt-to-Equity falls into.

HighTide Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

HighTide Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.528	+	11.445)	/	768.679
	=	0.02

HighTide Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.392	+	19.485)	/	590.659
	=	0.04

HighTide Therapeutics (HKSE:02511) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

HighTide Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Li Tan	2202 Interest of your spouse
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Li Li	2201 Interest of corporation controlled by you
Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you

HighTide Therapeutics Headlines

No Headlines